Arsanis Aims On Developing Monoclonal Antibodies For Better Treatments

Off late, there is a lot of talk about antibiotic resistance in the market and how bugs are now resistant to many of these antibiotics that have been helping us for the past few decades. Since new antibiotics take decades to develop, what options do we have left?

Well, thanks to companies like Arsanis, there are good treatment options available for us. Instead of developing antibiotics, Arsanis is concentrating efforts on developing monoclonal antibodies. These target infections but not by killing them but by reducing their capabilities of infecting others. By targeting organisms individually, treatment methods developed by Arsanis ensure that your normal flora is not disturbed either and you live a healthy life.

The Editorial Team

The Editorial Team comprises of Startup-Experts.

You may also like...